Publications
- The response of FLi1, EKLF, TP53 (p53), PU.1, MDM2 gene expression in 5q- syndrome to lenalidomide treatmentPublication without faculty affiliation
- Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower-risk myelodysplastic neoplasms2024 | First Faculty of Medicine, Faculty of Physical Education and Sport, Faculty of Science
- Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B12023 | Faculty of Science, Central Library of Charles University
- Luspatercept – a new contribution to the therapy of anaemia in patients with myelodysplastic syndrome2023 | First Faculty of Medicine
- Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial2023 | First Faculty of Medicine
- The benefit of luspatercept in the treatment of low‑risk myelodysplastic syndrome – case report2023 | First Faculty of Medicine
- Luspatercept představuje velký pokrok v terapii anemie u myelodysplastického syndromu2023 | First Faculty of Medicine
- RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS2022 | First Faculty of Medicine, Faculty of Science
- G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial2022 | First Faculty of Medicine, Faculty of Mathematics and Physics
- Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways2022 | First Faculty of Medicine
Loading network view...